Key facts
- This page summarizes Jason Raleigh Nunn's Form 4 filing for Zenas BioPharma, Inc. (ZBIO).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2026, 18:09.
Jason Raleigh Nunn - 15 Jun 2026 Form 4 Insider Report for Zenas BioPharma, Inc. (ZBIO)
- Reporting relationship
- Director
- Issuer ticker
- ZBIO
- Reported as of
- 15 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 Jun 2026, 18:09:56 UTC
- Prior SEC filing
- 18 Mar 2026
- Next SEC filing
- 04 Sep 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sasha Keough, attorney-in-fact for Jason R. Nunn
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Jason Raleigh Nunn filed Form 4 for Zenas BioPharma, Inc. (ZBIO) on 17 Jun 2026.
Change
- Previous filing in this sequence was filed on 18 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001444319
Primary reporting owner
Nunn Jason Raleigh
- Relationship
- Director
- Address
- 929 MAIN STREET, SUITE 200, REDWOOD CITY
- Signature
- /s/ Sasha Keough, attorney-in-fact for Jason R. Nunn
- Signature date
- 17 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ZBIO
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +18,500
- Change %
- Price
- $0.000000*
- Shares after
- 18,500
- Date
- 15 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 18,500
- Exercise price
- $18.71
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service.